Zimmer Biomet Holdings, Inc. (ZBH)
US — Healthcare Sector
Automate Your Wheel Strategy on ZBH
With Tiblio's Option Bot, you can configure your own wheel strategy including ZBH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZBH
- Rev/Share 39.5846
- Book/Share 63.3365
- PB 1.5563
- Debt/Equity 0.6046
- CurrentRatio 1.8722
- ROIC 0.051
- MktCap 19512454424.0
- FreeCF/Share 7.195
- PFCF 13.7035
- PE 23.674
- Debt/Assets 0.3312
- DivYield 0.0097
- ROE 0.0662
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ZBH | Rothschild & Co Redburn | -- | Buy | -- | $130 | Sept. 18, 2025 |
| Upgrade | ZBH | Roth Capital | Neutral | Buy | -- | $135 | July 15, 2025 |
| Upgrade | ZBH | JP Morgan | Neutral | Overweight | $125 | $128 | Dec. 17, 2024 |
| Initiation | ZBH | Wolfe Research | -- | Peer Perform | -- | -- | Sept. 10, 2024 |
News
Zimmer Biomet Focuses on Innovation Amid Growing Competition
ZBH
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Among Zimmer Biomet's knee solutions featured at the AAOS 2025, the newly cleared Persona Revision SoluTion Femur is expected to draw attention.
Read More
ZBH Stock to Gain From Global Expansion Amid Difficult FX Scenario
ZBH
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
Read More
ZBH Stock Hurt by Margin Concerns and Difficult Solvency
ZBH
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations.
Read More
About Zimmer Biomet Holdings, Inc. (ZBH)
- IPO Date 2001-07-25
- Website https://www.zimmerbiomet.com
- Industry Medical - Devices
- CEO Ivan Tornos
- Employees 17000
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.